Key Pharmaceuticals Limited
Mahesh Paigude is an experienced professional in the pharmaceutical industry, currently serving as the Head of Pharmacovigilance at Key Pharmaceuticals Limited since July 2015. With a diverse background in regulatory affairs and clinical research, Mahesh has held various roles including Senior Regulatory Affairs Manager for the EMEA region and Senior Clinical Research Scientist (BA/BE) at the same company. Prior to this, Mahesh held positions at Eli Lilly and Company as a Packaging Development Coordinator and at Procter & Gamble as a Registration Manager. Mahesh began the career as a Quality Assurance and Regulatory Coordinator at Cipla Ltd. Mahesh's academic credentials include a Master of Science in Formulation Science from the University of Greenwich and a Bachelor's Degree in Pharmaceutical Sciences from Savitribai Phule Pune University.
This person is not in the org chart
This person is not in any teams
Key Pharmaceuticals Limited
Based in Cambridgeshire, UK, with additional offices in Dublin and Pune, Key Pharmaceuticals has been involved in the development, manufacture and regulatory support of generic pharmaceuticals for 20 years. Through our technical knowledge and regulatory expertise, we have successfully developed, registered and launched 22 generic drugs in the UK, with many more in the pipeline. These products are now being prescribed across the country and delivered through our wide distribution network. Our products are used in hospitals, clinics and pharmacies up and down the UK. Through our product and regulatory experience, we are able to provide full support across the product lifecycle to those who require it. Across formulation, development, clinical, manufacturing scale up, registration, ongoing pharmacovigilance support, we will provide you a one stop shop to manage all of these elements. Key Pharmaceuticals is proud to be part of the Lexon Group, which has extensive wholesaling and retail operations within the UK, giving us an unparalleled level of support in serving the UK market. The extremely high quality of our medicines, which are developed and manufactured to the UK Medicines and Healthcare products Regulatory Agency (MHRA) GMP standards, has not gone un-noticed. International demand has been growing at a rapid pace, and our products are now available in markets across all 6 continents. With Marketing Authorisations granted by the MHRA and Certificate of Pharmaceutical Product (CPP) available, we are a natural fit for companies in both highly regulated and unregulated markets to expand their portfolio.